Our role in confronting this reproductive health crisis is to advocate for hematology/oncology pharmacy professionals and cancer patients. The Oath of a Pharmacist places on us the responsibility to advocate for change that improves patient care, and to consider the welfare of humanity and relief of suffering as primary concerns.

Oncology pharmacists have accepted the responsibility of being cancer medication experts and hold ourselves to the highest degree of professional, legal, and ethical conduct. We disagree with criminalizing patient care; we believe healthcare professionals should practice in a manner that best supports patients, without fear of retribution.

Limiting or restricting reproductive rights limits care options for people who are undergoing treatment for cancer while pregnant, and may limit the ability to deliver cancer therapy safely to patients who must avoid pregnancy during treatment. It obstructs patient access to safe, evidence-based cancer medications that, while highly effective at treating cancer, may also be used in medical abortions. Further, these restrictions make it more difficult for patients who survive cancer treatments to seek effective fertility treatments later.

As part of interdisciplinary cancer care teams:

  • We support shared decision-making between patients and their caregivers
  • We advocate for equitable access to all health services, including comprehensive screenings and patient-centered treatment choices
  • We oppose limiting access to care, which will disproportionately affect historically marginalized communities, including Black, Indigenous, and People of Color.
  • We oppose limiting access to appropriate medical care for those living in rural areas, and those with limited resources
  • We remain committed to helping patients navigate cancer treatment and supporting hematology/oncology pharmacists involved in their care

About HOPA: The Hematology/Oncology Pharmacy Association (HOPA) supports hematology/oncology pharmacy professionals and promotes the role of the pharmacist in collaborative cancer care. Founded in 2004, HOPA provides crucial education, networking, and advancement opportunities frequently sought by pharmacists, pharmacy interns, residents, fellows, students, technicians, researchers, and administrators who specialize in hematology/oncology pharmacy. Its vision is to ensure that all individuals affected by cancer have a hematology/oncology pharmacist as an integral member of their care team.

U.S. Capitol Building
Advocacy

What HOPA Members Should Know About the End of the 2025 U.S. Government Shutdown

On Wednesday, November 12, Congress passed a continuing resolution to re-open the government after a record 43-day shutdown. Here's what HOPA members should know about the bill and what's happening next.

Map of the sub-Saharan African region
Advocacy

HOPA Endorses ISOPP & UICC Statement on Ensuring International Cancer Drug Quality and Equity

ISOPP and UICC recently released a statement calling for quality and equity of cancer treatments in sub-Saharan Africa. HOPA has joined with oncology and pharmacy organizations worldwide to endorse their statement.

Images of DNA strands for DPYD genetic testing
Advocacy

HOPA Supports FDA Box Label Changes for DPYD Testing

We support the FDA's updated guidance concerning DPD deficiency and fluoropyrimidine drugs, and urge healthcare providers to integrate DPYD genetic testing into clinical practice.